文献速递肝病消化道肿瘤与早癌

T细胞:NASH发病机制与肝癌发生中的友与敌

T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis.
PubMed 文献 · Hepatology · 2022-02-04

综述阐述非酒精性脂肪性肝病(NAFLD)相关肝细胞癌(HCC)发病率随肥胖和代谢综合征流行而近乎指数上升,免疫检查点抑制剂对NAFLD诱导的HCC疗效不佳。文章聚焦T细胞群体在驱动慢性炎症向HCC进展中的关键作用,讨论代谢与免疫微环境交互塑造促瘤和免疫抑制微环境,并评述现有治疗策略的利弊与未来可能的新方法。

要点

  • NAFLD相关HCC发病率随肥胖和代谢综合征流行呈近乎指数增长。
  • 免疫检查点抑制剂对NAFLD诱导的HCC疗效不如对其他HCC有效。
  • T细胞在驱动慢性炎症向HCC进展中具有新发现的关键作用。

核心结论

  • 综述总结T细胞群体在NAFLD及NAFLD驱动HCC中的具体功能,并讨论代谢微环境对免疫细胞功能的影响及当前治疗策略的利弊与未来可能的新方法。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • NAFLD相关HCC的患病率随肥胖和代谢综合征的流行呈近乎指数增长。
  • 免疫检查点抑制剂对NAFLD诱导的HCC不如对其他HCC有效。
  • 代谢与免疫微环境相互作用重建促瘤和免疫抑制地形,导致抗癌治疗耐药。
  • 过去十年才揭示T细胞在驱动慢性炎症向HCC进展中的新关键作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In association with the pandemic spreading of obesity and metabolic syndrome, the prevalence of NAFLD-related HCC is increasing almost exponentially. In recent years, many of the underlining multifactorial causes of NAFLD have been identified, and the cellular mechanisms sustaining disease development have been dissected up to the single-cell level. However, there is still an urgent need to provide clinicians with more therapeutic targets, with particular attention on NAFLD-induced HCC, where immune checkpoint inhibitors do not work as efficiently. Whereas much effort has been invested in elucidating the role of innate immune response in the hepatic NAFLD microenvironment, only in the past decade have novel critical roles been unraveled for T cells in driving chronic inflammation toward HCC. The metabolic and immune microenvironment interact to recreate a tumor-promoting and immune-suppressive terrain, responsible for resistance to anticancer therapy. In this article, we will review the specific functions of several T-cell populations involved in NAFLD and NAFLD-driven HCC. We will illustrate the cellular crosstalk with other immune cells, regulatory networks or stimulatory effects of these interactions, and role of the metabolic microenvironment in influencing immune cell functionality. Finally, we will present the pros and cons of the current therapeutic strategies against NAFLD-related HCC and delineate possible novel approaches for the future.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ramadori P, Kam S, Heikenwalder M, et al. T cells: Friends and foes in NASH pathogenesis and hepatocarcinogenesis. Hepatology. 2022. PMID: 35023202. doi:10.1002/hep.32336

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。